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The inability to distinguish clearly between methamphetamine-related psychosis and
schizophrenia has led to the suggestion that “methamphetamine psychosis” does not
represent a distinct diagnostic entity but rather that the drug has triggered a vulnerability
to schizophrenia. We tested this possibility by exploring the latent class structure of
psychotic symptoms amongst people who use the drug and examining how these
latent symptom profiles correspond to a diagnosis of schizophrenia. Latent class analysis
was carried out on the lifetime psychotic symptoms of 554 current methamphetamine
users, of whom 40 met the DSM-IV criteria for schizophrenia. Lifetime diagnoses of
schizophrenia and individual psychotic symptoms were assessed using the Composite
International Diagnostic Interview. The chosen model found 22% of participants had a
high propensity to experience a wide range of psychotic symptoms (schizophrenia-like),
whereas the majority (56%) more specifically experienced persecutory delusions and
hallucinations (paranoid psychosis) and had a lower probability of these symptoms
than the schizophrenia-like class. A third class (22%) had a low probability of all
symptoms, with the exception of 34% reporting persecutory delusions. Participants in
the schizophrenia-like class were more likely to meet diagnostic criteria for schizophrenia
(26 vs. 3 and 1% for each of the other classes, p < 0.001) but the diagnosis failed
to encompass 74% of this group. These results are consistent with there being a
distinction between schizophrenia and methamphetamine-related psychotic symptoms,
both in terms of the propensity to experience psychotic symptoms, as well as the
symptom profile; however, this distinction may not be captured well by existing diagnostic
classifications.
Keywords: methamphetamine, amphetamine-related disorders, psychotic disorders, schizophrenia, diagnosis,
psychosis
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INTRODUCTION
Both current international classification systems for mental
disorders [i.e., the International Statistical Classification of
Diseases and Related Health Problems (ICD), 10th Revision (1)
and the Diagnostic and Statistical Manual, 5th edition, DSM-5
(2)] differentiate between psychosis related to methamphetamine
use (under the diagnosis of a substance-induced psychosis) and
primary psychotic disorders, such as schizophrenia. However, the
commonality between the symptom profile of methamphetamine
psychosis and acute paranoid schizophrenia (3, 4) often makes it
difficult to make a clear diagnosis, particularly in the early stages
of psychosis when prognostic information is not yet available
(5, 6). This frustration has led to concerns about the clinical
utility of the diagnostic categories and the potential ramifications
of misdiagnosis and failure to intervene early, particularly as
substance-induced presentations are often used as a justification
to exclude individuals from psychiatric care (7).
Most of the previous research that has attempted to
differentiate between schizophrenia and methamphetamine-
related psychosis use has done so by comparing symptom profiles
cross-sectionally. For example, Medhus and colleagues compared
individuals presenting with psychosis by whether or not they
tested positive for methamphetamine psychosis, and found no
significant differences in the severity of positive symptoms (5).
Hides et al. (6) similarly failed to find differences in the severity
of overall positive or negative symptoms in methamphetamine
users who met DSM-IV diagnostic criteria for substance-induced
psychosis and those who met DSM-IV criteria for a primary
psychotic disorder. Srisurapanont et al. (8) examined more
specific symptoms in methamphetamine psychosis, and, using
cluster analytic techniques, found evidence of negative, positive
and affective symptom clusters, which were almost the same
as that seen in a comparison group of patients diagnosed with
schizophrenia.
This lack of a clear diagnostic boundary between
methamphetamine-related psychosis and schizophrenia has
led Bramness and colleagues to propose that methamphetamine
psychosis does not represent a unique diagnostic entity, but
would be better conceptualized as a triggering of a schizophrenia
spectrum disorder in vulnerable individuals (9). This theory
is couched in the stress-vulnerability framework, whereby
vulnerability to psychosis occurs along a continuum of risk, and
exposure to methamphetamine interacts with this latent risk to
precipitate psychosis. Conceptualized within this framework,
a psychosis precipitated by methamphetamine need not be
considered a separate diagnostic entity from a primary psychotic
disorder. This possibility opens the door for such individuals to
be provided with an early intervention approach for psychosis,
including antipsychotic treatment, as would be the case for
individuals with a primary psychotic disorder.
On the other hand, methamphetamine use is associated
with different prognostic outcomes amongst people presenting
with psychosis (10–12). Case reports (13) and experimental
inductions of methamphetamine psychosis (4) suggest that it
is a transient phenomenon that does not warrant ongoing
anti-psychotic treatment. There is also emerging evidence
that the symptom profile associated with methamphetamine
use can be distinguished from that associated with primary
psychotic disorders, in that specific types of psychotic symptoms
(particularly non-persecutory delusions) are risk markers for
more persistent psychosis (14) and a diagnosis of a primary
psychotic disorder (15, 16). Together, this evidence suggests
a potential clinical benefit in identifying methamphetamine-
related psychosis as distinct from non-organic psychotic
processes.
One way to test whether there is any merit in retaining the
diagnostic category of methamphetamine-induced psychosis (cf.
the triggering of schizophrenia) is using latent class analysis.
Latent class analysis classifies population heterogeneity into
categorical groups of homogeneous individuals which may have
implications for classification (i.e., diagnosis), prognosis (i.e.,
longitudinal course), and treatment (i.e., propensity to respond
to different treatments) (17). Latent class analysis has been
increasingly applied in psychiatry to identify subgroups of
patients or clinical markers that may have clinical utility but
which are obscured by more traditional methods of analysis,
such as pairwise group comparisons that presuppose diagnostic
structures and their relationship to clinical characteristics (18–
20). In latent class analysis, the presence of a group of people
who are homogenous in their symptom profile should present
as a single latent class. The presence of more than one latent
class would suggest multiple groups of individuals who are
distinguishable based on their symptom profile, and would be
consistent with a need for different diagnostic categories to reflect
these different symptom typologies.
Here we use latent class analysis to examine whether
there is evidence of different classes of psychosis amongst
people who use methamphetamine, as well as to understand
how these classes correspond to the diagnostic category of
schizophrenia. We hypothesized that if psychosis amongst
people who use methamphetamine reflects the triggering of
schizophrenia, then we would detect a single latent profile
of psychotic symptoms, thus reflecting the symptom profile
associated with schizophrenia. Conversely, if methamphetamine
induced a psychosis that was distinct from schizophrenia then
this should manifest as a separate class reflecting the symptom
profile associated with methamphetamine-induced psychosis.
Essentially, the presence of two or more latent classes would
suggest different psychosis typologies in the population, and this
would be more consistent with a need for multiple diagnostic
categories to capture the heterogeneity in psychosis amongst
people who use methamphetamine.
MATERIALS AND METHOD
Participants and Procedure
Participants were drawn from two Australian-based studies of
methamphetamine users (21, 22). Data on 178 participants were
taken from a cross-sectional survey conducted in Canberra in
2016–17 of volunteers recruited from the general community
(via advertisements at needle and syringe programs, online
and other public locations, and word of mouth) who used
methamphetamine at least monthly and who were aged 18
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years or older (21). Data for a further 376 participants were
drawn from a longitudinal cohort study, the Methamphetamine
Treatment Evaluation Study (MATES) (22, 23), conducted in
Sydney and Brisbane from 2006 to 2011, and which included
400 participants seeking treatment for methamphetamine
use; and, a further 101 dependent methamphetamine users
recruited from the community. MATES participants had to
be 16 years or older and not have been incarcerated, in
drug treatment or any in-patient treatment for the month
prior to enrollment. Participants from the MATES cohort
were not included if they did not meet DSM-IV criteria for
methamphetamine dependence in the year prior to recruitment
(n = 17) or they did not complete the 3-month follow-
up interview where a diagnosis of schizophrenia was made
(n = 92). Interviews were conducted face-to-face or by phone.
All participants were volunteers who provided either written
or verbal informed consent and were reimbursed (up to
AUD40 per interview). Verbal informed consent procedures
were approved by the institutional Human Research Ethics
Committee.
Measures
Psychosis Measures
A DSM-IV lifetime diagnosis of schizophrenia was made using
the Composite International Diagnostic Interview (CIDI)
Version 2.1 (24). Negative symptoms, disorganization and
catatonia were not assessed because of the difficulty assessing
these symptoms retrospectively across the participant’s lifespan
based on current self-report. Lifetime psychotic symptoms were
based on the symptom criteria for schizophrenia as assessed in
the pertinent section of the CIDI (24). Delusions were grouped
as persecutory, thought projection, thought interference,
passivity, reference, other delusions (erotomania, jealousy,
mind reading). Hallucinations were categorized as complex
auditory hallucinations, other auditory hallucinations, visual
hallucinations, and other hallucinations (olfactory, gustatory
and tactile). See the Supplementary material for further
detail.
Substance Use
Days of methamphetamine use and other substance use
(cannabis, heroin, cocaine, ecstasy, hallucinogens, alcohol,
and tobacco) in the previous 4 weeks was assessed using the
Opiate Treatment Index (25). Self-reported abstinence from
methamphetamine was confirmed in a sub-sample of the
MATES cohort using hair toxicology, with false reporting
of abstinence occurring in only 6% of cases (22). Other
methamphetamine use measures included age of first use,
main route of methamphetamine administration in the
previous month, as well as severity of methamphetamine
dependence in the previous month, assessed using the
Severity of Dependence Scale (SDS) (26). Dependence
on methamphetamine was defined as a score of 4 or
greater on the SDS scale, which corresponds to a CIDI
diagnosis of severe dependence with 71% sensitivity and 77%
specificity (27). Baseline data are reported for the MATES
participants.
Statistical Analysis
Latent class analysis in MPlus version 7.2 (28) was applied to the
binary symptom variables using a maximum likelihood estimator
with robust standard errors. Latent models were fitted using
600 random starting values to ensure replication of the final
log-likelihood value. Modeling was performed sequentially by
examining whether each additional class significantly improved
the fit of the model to the data, as indicated by the Voung-
Lo-Mendell-Rubin Likelihood Ratio Test (VLMR LRT) and the
parametric bootstrapped Likelihood Ratio Test (BLRT) (29, 30).
Owing to a sample size that may be sensitive to small chi-
square changes, entropy, the Bayesian Information Criterion
(BIC) and Akaike Information Criterion (AIC) were also used to
compare model fit. Consideration of all goodness of fit indices
and parsimony determined the number of classes to be extracted.
Participants’ most likely class was determined from the latent
class posterior distribution.
Other data analyses were performed using Stata SE version
14.1 (31). Group comparisons were made using a Pearson’s Chi
Square test for categorical data, t-tests for continuous data, and
a median comparison test for skewed continuous data (where
medians and interquartile ranges [IQR] are reported rather
than means and standard deviations [SDs]). Receiver Operating
Characteristics was conducted using the “roctab” command and
the “pvenn2” was used to produce the related Venn diagram. All
tests were two-sided with significance set at p < 0.05.
RESULTS
Characteristics of the Sample
Participants (n = 554) had a mean (SD) age of 34.3 (9.5)
years, 70% were male, and 89% were Australian born. They
had used methamphetamine for a mean (SD) of 15.4 (9.0)
years and they had used on a median (IQR) of 14 (6–
20) days in the previous month. For participants who had
used methamphetamine in the previous month (95%), 86%
usually took crystalline methamphetamine. The main route of
administration was injection (75%), with 18% smoking and 6%
swallowing or snorting the drug. The most commonly used
other drugs in the previous month were tobacco (95%), cannabis
(79%), and alcohol (68%), with other drugs being used less
commonly (heroin 31%, ecstasy 21%, cocaine 21%, inhalants 6%,
and hallucinogens 6%).
Lifetime psychotic symptoms were reported by 87% of
participants, most commonly persecutory delusions (74%),
auditory hallucinations (49%: 27% complex and 23% other),
visual hallucinations (43%) and other hallucinations (56%)
(Table 1). Seven percent of participants (n= 40)met the DSM-IV
criteria for a lifetime diagnosis of schizophrenia.
Latent Class Analysis
A two-class model significantly improved fit over a one class
model (Table 2). A three-class model further improved model fit.
The three-class model was selected based on significant VLMR
and LRT tests, and lower AIC and adjusted BIC (Table 2). A
sensitivity analysis was conducted that included a covariate in
the analysis that identified the study from which participants
were recruited to confirm that this was not unduly influencing
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TABLE 1 | Participant characteristics by latent class.
“Schizophrenia-like”
(n = 123)
“Paranoid
psychosis” (n = 309)
“Few symptoms”
(n = 122)
Total sample
(n = 554)
SYMPTOMS (%)
Persecutory delusions 98 80*** 34***††† 74
Delusions of reference 54 10*** 0***††† 18
Thought projection 74 12*** 1***††† 23
Thought interference 63 4*** 0***††† 16
Delusions of passivity 58 5*** 1***††† 16
Other delusions 75 27*** 2***††† 32
Visual hallucinations 70 49*** 0***††† 43
Complex auditory hallucinations 74 17*** 3***††† 27
Other auditory hallucinations 11 36*** 0***††† 23
Other hallucinationsa 85 67*** 0***††† 56
DEMOGRAPHICS
Age (median years) 33 33 35 34
Male (%) 71 69 75 71
Years of schooling (median) 10 10 10 10
Unemployed (%) 82 75 73 76
Immigrant (%) 17 8** 12 11
METHAMPHETAMINE USE
Duration of use (median years) 15 14 15 14
Days of use (median) 14 15 13 14
Injecting (%) 80 71 71 73
SDS score (%) 9 8 7 8
Dependent (%) 81 79 74 78
OTHER DRUGS USED IN THE PAST MONTH (%)
Tobacco 98 93* 96 95
Cannabis 82 79 78 79
Alcohol 72 69 61 68
Ecstasy 15 25* 14† 21
Cocaine 20 23 20 21
Hallucinogens 6 7 6 6
Inhalants 6 7 2 6
Heroin 28 33 30 31
No. other drug classes used in past month (mean) 3.3 3.4 3.1† 3
DSM-IV criteria for schizophrenia (%) 26 3*** 0*** 7
*p < 0.05, **p < 0.01, ***p < 0.001, relative to the schizophrenia-like class.
†
p< 0.05,
†††
p < 0.001, relative to the paranoid psychosis class.
aTactile, gustatory or olfactory.
the classes detected. A comparable pattern of results was found.
Analysis of a four-class model is not reported as the highest log-
likelihood value was not replicated and thus was excluded from
further consideration.
The symptom profile associated with each class in the
three-class model is shown in Figure 1, and the characteristics
of each class are shown in Table 1. The first class (22% of
participants) had a very high probability of reporting almost
all types of psychotic symptoms and were significantly more
likely to meet the DSM-IV criteria for schizophrenia than
the other two latent classes (26 vs. 3 and 0%, respectively;
Table 1). We labeled this group “schizophrenia-like.” The
majority of participants (56%) had a symptom profile
that was characterized more specifically by persecutory
delusions (80%) and various hallucinations (17–67%; labeled
“paranoid psychosis”). Participants in this class and had a
significantly lower probability of all symptom types than
the schizophrenia-like group and only 3% met the DSM-
IV diagnostic criteria for schizophrenia. The third class
comprised a minority of participants (22%) who had a very low
probability of all symptoms with the exception of 34% reporting
persecutory delusions (labeled “few symptoms”); none of the
participants in this class met the DSM-IV diagnostic criteria for
schizophrenia.
There were few differences in the demographic or
polysubstance use characteristics of the three classes. The
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TABLE 2 | Model fit statistics for latent class analysis.
Full sample (N = 554)
Two-class Three-class
Class membership 1. n = 169 (31%)
2. n = 385 (69%)
1. n = 123 (22%)
2. n = 309 (56%)
3. n = 122 (22%)
Bootstrap LRT (p-value) −7475 (<0.001) −7119 (<0.001)
Entropy 0.796 0.761
AIC/Adjusted BIC 5498/5522 5384/5421
VLMR LRT (p-value) −7475 (<0.001) −7119 (0.003)
Akaike’s information criterion (AIC), Bayesian information criterion (BIC), Voung-Lo-
Mendell-Rubin (VLMR), likelihood ratio test (LRT).
paranoid psychosis class was less likely to be immigrant, more
likely to use ecstasy and less likely to smoke tobacco, while
the few symptom class had lower levels of polysubstance use
(Table 1).
Receiver Operating Characteristics (ROC)
Analysis
To assess concordance between the DSM-IV diagnosis of
schizophrenia and the schizophrenia-like class we detected in
our LCA analysis, we conducted a ROC analysis with the
schizophrenia-like class (n = 123) as the reference variable and
the DSM-IV diagnosis of schizophrenia (n = 40) as the class
variable. Although there was significant concordance between
meeting the DSM-IV criteria for schizophrenia and membership
in the schizophrenia-like class (ROC area = 0.62, 95% CI 0.58–
0.66), and the DSM-IV criteria had good specificity in detecting
participants in the schizophrenia-like class (98%), sensitivity
was poor (26%). Thus, 74% of participants who fell into the
schizophrenia-like class did not meet the DSM-IV diagnostic
criteria for schizophrenia (Figure 2).
DISCUSSION
These findings suggest the presence of three latent
classes of psychosis vulnerability amongst people who use
methamphetamine, including two distinct classes of individuals
who have vulnerability to psychotic symptoms, but differ in
both their symptom profile and their probability of psychotic
symptoms. The identification of multiple relatively distinct
latent classes of psychosis (i.e., different typologies of psychosis)
in this population is inconsistent with the notion of a single
diagnostic category, as would be expected if methamphetamine
was triggering schizophrenia. Importantly, we found latent
symptom profiles that aligned conceptually with the existing
diagnostic groupings of schizophrenia and methamphetamine-
induced psychosis. Specifically, the larger of the two groups
had a symptom profile comprised of persecutory delusions
and hallucinations, consistent with the classic notions of
methamphetamine-induced psychosis (32). In contrast, a
minority of people who used the drug had a comparatively high
probability of all psychotic symptoms and were significantly
more likely to meet the DSM-IV diagnostic criteria for
schizophrenia.
The presence of multiple latent psychotic symptom profiles
in this population does not preclude a common etiology for
psychosis vulnerability, in the sense that different psychotic
symptom profiles could plausibly stem from a common
underlying vulnerability, as suggested by Bramness et al. (9).
For example, influenza results in symptom clusters in multiple
organ systems, which present at different time in the course of
the illness, and can vary in how they are expressed between
individuals. However, the reliance on clinical syndromes over
etiological mechanisms to define psychiatric disordersmeans that
diagnostic categories need to carry weight in their usefulness
to describe and treat patients, and to understand their likely
prognosis. In this sense, our data suggest that there are
meaningfully different sub-populations of psychosis amongst
people who use methamphetamine (both in terms of their
propensity to experience psychotic symptoms and their symptom
profile). Further research is needed to determine the prognostic
utility of these identified typologies and how they could be better
captured using diagnostic criteria.
Although the identified classes of psychosis vulnerability bear
some resemblance to existing diagnostic categories, individuals
who had a high probability of psychosis (the schizophrenia-like
class) were not sufficiently well captured by the diagnostic criteria
for schizophrenia, or at least not as they are assessed through
the CIDI. This lack of sensitivity to identify methamphetamine
users who have a high probability of psychosis is likely to
underpin the challenges faced by clinicians in being able to apply
diagnostic criteria to identify individuals who would benefit from
early intervention strategies for a psychotic disorder (7). That
said, we also show that the majority of individuals who use
methamphetamine do not reach a threshold of symptom severity
associated with schizophrenia, and this has potentially important
implications for treatment, in that these individuals may not
benefit from sustained antipsychotic treatment and may require
a different model of care.
The poor sensitivity of the diagnostic criteria for
schizophrenia to detect individuals who we identified as
having a schizophrenia-like psychosis is likely to be due to the
poor sensitivity of the CIDI to detect schizophrenia (relative
to clinician ratings) more generally (33). However, it could
also reflect poor sensitivity of the DSM criteria in the context
of comorbid methamphetamine use. The latter view has been
flagged by researchers and clinicians (7), and suggested by
prospective data, in which 30% of individuals initially diagnosed
with an amphetamine-related psychosis are re-diagnosed with a
primary psychotic disorder within 10 years (34). The existence of
this orphan category of individuals who had a high probability
of psychosis, but who failed to meet the DSM-IV criteria for
schizophrenia, may explain clinical descriptions of a persistent
or prolonged form of psychosis amongst people who use
methamphetamine (as distinct from schizophrenia), and that
this phenomena shares commonality with schizophrenia both
in terms of its familial morbidity (35) and symptom profile
(14). These individuals may have an underlying vulnerability
to schizophrenia that is triggered by methamphetamine, or
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FIGURE 1 | Lifetime symptom prevalence for the three-class model.
conversely, are using the drug as a form of self-medication to
manage a premorbid vulnerability or prodromal state.
Our finding suggest that assessing the past experience of
specific types of psychotic symptoms may help to identify
methamphetamine-related psychosis patients who would benefit
from an early intervention for a psychotic disorder. Specifically,
we found a broader symptom profile (i.e., presence of non-
persecutory delusions and complex auditory hallucinations)
amongst individuals who had a schizophrenia-like psychosis
profile. This finding aligns with our previous research which
found that the presence of these symptoms was associated
with psychosis that persisted beyond methamphetamine use
and that their presence in first episode psychosis portended
a subsequent diagnosis of schizophrenia (14–16). Conversely,
evidence of a second class of people with paranoid psychosis,
similar to the current conceptualization of methamphetamine-
induced psychosis, suggests that individuals who report having
only ever experienced persecutory delusions (with or without
hallucinations) are likely to be at much lower risk of having
schizophrenia and may benefit more from substance use
treatment to reduce their risk of subsequent psychotic episodes
rather than ongoing antipsychotic treatment. A caution here
is that we did not have prognostic data available to validate
the clinical utility of the latent classes of psychosis that we
detected. For this reason we suggest that the monitoring of
symptoms, including their response to clinical interventions,
remains imperative.
The presence of a sub-group of individuals who report
having experienced few psychotic symptoms, or only paranoia,
suggests differential vulnerability to methamphetamine-related
psychosis. This observation is consistent with previous literature
showing that not all people who use the drug develop psychotic
FIGURE 2 | Venn diagram showing overlap between the schizophrenia-like
class and a DSM-IV diagnosis of schizophrenia.
symptoms (36) and the continuum of psychosis vulnerability
observed at a population level, this owing to the many genetic
and environmental factors thought to contribute to psychosis
risk (37). The preponderance of persecutory delusions across all
classes of psychosis vulnerability, even amongst participant with
no other psychotic symptoms, may reflect suspiciousness related
to the illicit-drug using context (e.g., fear of retribution, social
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conflict, police surveillance). It could also reflect a continuum
of vulnerability whereby persecutory delusions are expressed
at lower levels of psychosis proneness, and conversely, that
higher levels of vulnerability are required for the expression of
hallucinations and non-persecutory delusions (36).
A limitation of the current study was that schizophrenia
was the only primary psychotic disorder diagnosed and only a
small number of participants met the criteria for this disorder.
However, we did not exclude psychotic symptoms that occurred
in the context of depression or mania when making this
diagnosis, and therefore any participants meeting the symptom
criteria for positive symptoms (i.e., presence of delusions and/or
hallucinations) in the context of these affective disturbances
would have been captured under a diagnosis of schizophrenia.
In addition, we used a DSM-IV diagnosis of schizophrenia (cf.
DSM-5) andwe did not include negative symptoms, or symptoms
of disorganization or catatonia when making the diagnosis. The
inclusion of these symptoms may have improved alignment
between the diagnosis of schizophrenia and our high probability
of psychosis sub-population, as some of these symptoms have
been shown to differentiate between sub-classes of psychosis
proneness and predict conversion to psychotic disorders (20).
Finally, we did not attempt to diagnose substance-induced
psychosis in this sample, so although we observed a symptom
profile consistent with methamphetamine-related psychosis, we
cannot confirm whether these participants would have met
criteria for this disorder.
The finding that immigrants had a higher probability of
psychosis is consistent with migration being a risk factor for
psychosis (38), but it may also reflect racial differences in
psychosis risk. It is important to note that our sample consisted
of mostly Australian born individuals, and this may affect how
the findings generalize to other racial groups and cultures. There
was also a high rate of polysubstance use, including cannabis
use, in this sample. Cannabis use in particular has been related
to increased risk of developing a psychotic disorder (39, 40),
and more cannabis frequent use is associated with an elevated
occurrence of psychotic symptoms amongst people who use
methamphetamine (23). However, we did not find any evidence
of greater polysubstance use, including cannabis use, amongst
participants who had a high probability of psychosis in this
sample.
In sum, we demonstrate the importance of retaining the
diagnostic category of methamphetamine-related psychosis (i.e.,
substance-induced psychosis in the DSM-5) as an alternative
to schizophrenia, as it is clear that the majority of people
who use methamphetamine have a relatively low propensity to
experience psychotic symptoms that would meet the criteria
for schizophrenia, and have a different symptom typology.
Prognostic data would be needed to confirm the full diagnostic
utility of these latent sub-populations of psychosis vulnerability.
However, the cross-sectional perspective provided here cautions
against assuming that all psychosis arising in the context of
methamphetamine use reflects schizophrenia. In addition, we
found that the DSM-IV diagnostic criteria for schizophrenia
had limited utility for identifying methamphetamine users who
had a high probability of psychosis, suggesting that further
development of the criteria are needed to improve the detection
of psychotic disorders in this population.
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